"ruxolitinib" meaning in All languages combined

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "ruxolitinib (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        {
          "kind": "other",
          "name": "English entries with incorrect language header",
          "parents": [
            "Entries with incorrect language header",
            "Entry maintenance"
          ],
          "source": "w"
        },
        {
          "kind": "topical",
          "langcode": "en",
          "name": "Pharmaceutical drugs",
          "orig": "en:Pharmaceutical drugs",
          "parents": [
            "Drugs",
            "Matter",
            "Pharmacology",
            "Chemistry",
            "Nature",
            "Biochemistry",
            "Medicine",
            "Sciences",
            "All topics",
            "Biology",
            "Fundamental"
          ],
          "source": "w"
        }
      ],
      "examples": [
        {
          "ref": "2015 July 14, Li Zhang, Handong Wang, Orazio Taglialatela-Scafati, “Multiple Mechanisms of Anti-Cancer Effects Exerted by Astaxanthin”, in Marine Drugs, volume 13, →DOI",
          "text": "For example, Gallipoli et al. reported that combination of nilotinib with ruxolitinib could induce apoptosis in chronic myeloid leukemia (CML) stem cells through inhibiting JAK-2/STAT-5 signaling pathway.",
          "type": "quotation"
        },
        {
          "ref": "2021 December, Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, Massimo Gadina, John J. O’Shea, “A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?”, in Arthritis & Rheumatology, volume 73, number 12, →DOI, page 2168",
          "text": "The first jakinib to enter clinical trials, initially for renal transplantation, was tofacitinib, which inhibits JAK1/JAK2/JAK3; however, ruxolitinib, a JAK1/JAK2 inhibitor, was the first agent to receive approval, as a treatment for myeloproliferative neoplasms that often exhibit gain-of-function JAK2 mutations.",
          "type": "quotation"
        }
      ],
      "glosses": [
        "A medication belonging to the class of Janus kinase inhibitors, used for the treatment of several diseases including myelofibrosis and polycythemia vera."
      ],
      "id": "en-ruxolitinib-en-noun-6PniizIZ",
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "medication",
          "medication"
        ],
        [
          "Janus kinase",
          "Janus kinase"
        ],
        [
          "inhibitor",
          "inhibitor"
        ],
        [
          "treatment",
          "treatment"
        ],
        [
          "disease",
          "disease"
        ],
        [
          "myelofibrosis",
          "myelofibrosis"
        ],
        [
          "polycythemia vera",
          "polycythemia vera"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A medication belonging to the class of Janus kinase inhibitors, used for the treatment of several diseases including myelofibrosis and polycythemia vera."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ]
    }
  ],
  "word": "ruxolitinib"
}

{
  "head_templates": [
    {
      "args": {
        "1": "-"
      },
      "expansion": "ruxolitinib (uncountable)",
      "name": "en-noun"
    }
  ],
  "lang": "English",
  "lang_code": "en",
  "pos": "noun",
  "senses": [
    {
      "categories": [
        "English entries with incorrect language header",
        "English lemmas",
        "English nouns",
        "English terms with quotations",
        "English uncountable nouns",
        "en:Pharmaceutical drugs"
      ],
      "examples": [
        {
          "ref": "2015 July 14, Li Zhang, Handong Wang, Orazio Taglialatela-Scafati, “Multiple Mechanisms of Anti-Cancer Effects Exerted by Astaxanthin”, in Marine Drugs, volume 13, →DOI",
          "text": "For example, Gallipoli et al. reported that combination of nilotinib with ruxolitinib could induce apoptosis in chronic myeloid leukemia (CML) stem cells through inhibiting JAK-2/STAT-5 signaling pathway.",
          "type": "quotation"
        },
        {
          "ref": "2021 December, Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, Massimo Gadina, John J. O’Shea, “A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?”, in Arthritis & Rheumatology, volume 73, number 12, →DOI, page 2168",
          "text": "The first jakinib to enter clinical trials, initially for renal transplantation, was tofacitinib, which inhibits JAK1/JAK2/JAK3; however, ruxolitinib, a JAK1/JAK2 inhibitor, was the first agent to receive approval, as a treatment for myeloproliferative neoplasms that often exhibit gain-of-function JAK2 mutations.",
          "type": "quotation"
        }
      ],
      "glosses": [
        "A medication belonging to the class of Janus kinase inhibitors, used for the treatment of several diseases including myelofibrosis and polycythemia vera."
      ],
      "links": [
        [
          "pharmacology",
          "pharmacology"
        ],
        [
          "medication",
          "medication"
        ],
        [
          "Janus kinase",
          "Janus kinase"
        ],
        [
          "inhibitor",
          "inhibitor"
        ],
        [
          "treatment",
          "treatment"
        ],
        [
          "disease",
          "disease"
        ],
        [
          "myelofibrosis",
          "myelofibrosis"
        ],
        [
          "polycythemia vera",
          "polycythemia vera"
        ]
      ],
      "raw_glosses": [
        "(pharmacology) A medication belonging to the class of Janus kinase inhibitors, used for the treatment of several diseases including myelofibrosis and polycythemia vera."
      ],
      "tags": [
        "uncountable"
      ],
      "topics": [
        "medicine",
        "pharmacology",
        "sciences"
      ]
    }
  ],
  "word": "ruxolitinib"
}